real-time news and commentary for investors
Monday, Dec 10
2012, 4:23 PM
Myriad Genetics (MYGN) enters into a research collaboration with Sanofi (SNY) and Population...
Myriad Genetics (MYGN) enters into a research collaboration with Sanofi (SNY) and Population Health Research Institute at Hamilton Health Sciences and McMaster University to perform protein biomarker research for the Outcome Reduction with Initial Glargine Intervention, or ORIGIN, study. The study is the world's longest and largest randomized clinical trial in pre/early-stage diabetes. The collaboration could represent up to $10M in revenue for MYGN over the next two fiscal years, and is factored into FY13 revised guidance.